FMDRX
Price
$34.44
Change
-$0.04 (-0.12%)
Updated
Jul 31 closing price
Net Assets
9.45B
RSEYX
Price
$14.22
Change
-$0.03 (-0.21%)
Updated
Jul 31 closing price
Net Assets
893.16M
Interact to see
Advertisement

FMDRX vs RSEYX

FMDRX vs RSEYX Comparison Chart in %
View a ticker or compare two or three
VS
FMDRX vs. RSEYX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FMDRX is a Hold and RSEYX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FMDRX has more cash in the bank: 9.45B vs. RSEYX (893M). RSEYX pays higher dividends than FMDRX: RSEYX (3.29) vs FMDRX (1.74). FMDRX was incepted earlier than RSEYX: FMDRX (13 years) vs RSEYX (20 years). FMDRX (0.89) is less costly to investors than RSEYX (0.82). RSEYX is a more actively managed with annual turnover of: 63.00 vs. FMDRX (42.28). RSEYX has a lower initial minimum investment than FMDRX: RSEYX (0) vs FMDRX (1000000). FMDRX annual gain was more profitable for investors over the last year : 9.64 vs. RSEYX (9.13). RSEYX return over 5 years is better than : 20.05 vs. FMDRX (12.18).
FMDRXRSEYXFMDRX / RSEYX
Total Expense Ratio0.890.82109%
Annual Report Gross Expense Ratio0.890.82109%
Fund Existence13 years20 years-
Gain YTD7.4248.31389%
Front LoadN/AN/A-
Min. Initial Investment10000000-
Min. Initial Investment IRAN/AN/A-
Net Assets9.45B893M1,059%
Annual Yield % from dividends1.743.2953%
Returns for 1 year9.649.13106%
Returns for 3 years17.3028.9460%
Returns for 5 years12.1820.0561%
Returns for 10 years27.8750.6055%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DBOCX25.380.10
+0.40%
BNY Mellon Balanced Opportunity C
DRRAX17.660.02
+0.11%
BNY Mellon Global Real Return - A
VZICX38.380.03
+0.08%
Vanguard International Core Stock Adm
PFPMX41.20-0.04
-0.10%
Parnassus Mid Cap Institutional
LYFIX17.94-0.50
-2.71%
AlphaCentric Life Sciences & Hlthcare I